Moneycontrol PRO
you are here: HomeNewsBusiness

COVID-19 may derail recovery of Indian banks by years: S&P Global Ratings

The US-based rating agency expects non-performing loans in Indian banks will hit a fresh high, raising credit costs, and putting pressure on ratings.

June 30, 2020 / 05:44 PM IST

S&P Global Ratings on June 30 said the coronavirus pandemic may push back the recovery of India's banking sector by years, which could hit credit flows and, ultimately, the economy.

The US-based rating agency expects non-performing loans in Indian banks will hit a fresh high, raising credit costs, and putting pressure on ratings.

"In our base case, we expect the non-performing loans to shoot up to 13-14 percent of total loans in the fiscal year ending March 31, 2021, compared with an estimated 8.5 percent in the previous fiscal year," said S&P Global Ratings credit analyst Deepali Seth-Chhabria.

Track this blog for latest updates on the coronavirus crisis

Moreover, the resolution of these bad-debt situations will likely unfold slowly, which means banks may also be saddled with a huge stock of bad loans next year.


COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more

"We assume only about a 100 basis point improvement in non-performing loans in fiscal 2022 (year ending March 31, 2022)," she added.

S&P Global Ratings credit analyst Geeta Chugh said the effect on finance companies will be more pronounced than on banks.

"Some finance companies lend to weaker customers and have high reliance on wholesale funding. These companies were already facing a trust deficit since the 2018 default of Infrastructure Leasing & Financial Services. Finance companies also face accentuated liquidity risks due to high proportion of borrowers opting for loan moratorium,” she said.

After years of deterioration, asset quality in the Indian banking system had improved over the past 18 months, helped by higher write-offs, slower accretion of bad loans, and resolution of some big cases under the new bankruptcy law.

“Nevertheless, Indian banks were still working through a formidable overhang of non-performing assets when the COVID crisis struck. This largely derailed that rehabilitation process,” S&P added.

Follow our full coverage of the coronavirus pandemic here.
first published: Jun 30, 2020 04:00 pm
ISO 27001 - BSI Assurance Mark